Alliances
The military reviewed bids from 31 suitors and is good to Dec. 20, 2022.
The parent company of JSR Life Sciences snapped up CRO Crown Bioscience International for $400M, the company announced this morning.
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.
Under terms of the deal, Boehringer has the option to acquire Autifony’s Kv3.1/3.2 positive modulator platform, which includes the company’s lead compound AUT00206.
Chiome Bioscience says it announces termination of candidate antibody related joint research contract, which was signed between the co and Chugai Pharma, as the contract has expired on Dec. 31
Amgen tapped two companies to receive its coveted 2017 Golden Ticket at LabCentral.
reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.
Kangmei will supply the JV with 95% of the $7.6M in cash, while BGI will contribute the remaining 5% of the JV’s value with instruments and technology.
Daiichi Sankyo informed Nektar that it was terminating a collaboration and licensing deal, effective Feb. 4, 2018.
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
PRESS RELEASES